Metrika

  • citati u SCIndeksu: [3]
  • citati u CrossRef-u:[3]
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:96
  • preuzimanja u poslednjih 30 dana:85

Sadržaj

članak: 1 od 1  
2015, vol. 65, br. 2, str. 129-146
Lajmska borelioza - epidemiologija, klinička slika i terapija
Univerzitet u Beogradu, Farmaceutski fakultet, Institut za mikrobiologiju i imunologiju

e-adresajelena@pharmacy.bg.ac.rs
Sažetak
Lajmska borelioza je multisistemska bolest koju karakteriše širok spektar kliničkih manifestacija. U Evropi je primarno prouzrokovana vrstama B. afzelii, B. garinii i B. burgdorferi sensu stricto, ali Borrelia spielmanii, Borrelia valaisiana, Borrelia lusitaniae and Borrelia bissettii se takođe navode kao retki ili potencijalni uzročnici oboljenja kod ljudi. U Severnoj Americi, kao jedini humani patogen, dokazana je vrsta B. burgdorferi sensu stricto. Najčešća klinička manifestacija lajmske borelioze je kožna lezija, erythema migrans, koja može da prođe spontano, bez terapije antibioticima. Međutim, patogen se može širiti do drugih delova kože i organa i tako prouzrokovati teže manifestacije kako na koži, tako i na nervnom sistemu, zglobovima i/ili srcu, pri čemu je terapija antibioticima neophodna. Najčešće korišćeni antibiotici u terapiji lajmske borelioze su: amoksicilin, ceftriakson, cefuroksim, doksiciklin i azitromicin.
Reference
Aguero-Rosenfeld, M.E., Wang, G., Schwartz, I., Wormser, G.P. (2005) Diagnosis of lyme borreliosis. Clinical microbiology reviews, 18(3): 484-509
Ates, L., Hanssen-Hübner, C., Norris, D.E., Richter, D., Kraiczy, P., Hunfeld, K. (2010) Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi. Ticks and tick-borne diseases, 1(1): 30-4
Aucott, J., Morrison, C., Munoz, B., Rowe, P.C., Schwarzwalder, A., West, S.K. (2009) Diagnostic challenges of early Lyme disease: Lessons from a community case series. BMC Infectious Diseases, 9(1): 79
Bacon, R.M., Kugeler, K.J., Mead, P.S. (2008) Centers for Disease Control and Prevention. Surveillance for Lyme disease-United States, 1992-2006. MMWR Morb Mortal Wkly Rep., 57: 1-9; http://www.cdc.gov/lyme/stats/index.html (15.05.2015)
Carlsson, S., Granlund, H., Jansson, C., Nyman, D., Wahlberg, P. (2003) Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections. Scandinavian journal of infectious diseases, 35(1): 31-3
Collares-Pereira, M., Couceiro, S., Franca, I., Kurtenbach, K., Schäfer, S.M., Vitorino, L., Gonçalves, L., Baptista, S., Vieira, M.L., Cunha, C. (2004) First isolation of Borrelia lusitaniae from a human patient. Journal of clinical microbiology, 42(3): 1316-8
Dam, A.P., Kuiper, H., Vos, K., Widjojokusumo, A., Jongh, B.M., Spanjaard, L., Ramselaar, A.C., Kramer, M.D., Dankert, J. (1993) Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clinical infectious diseases, 17(4): 708-17
Dressler, F., Whalen, J.A., Reinhardt, B.N., Steere, A.C. (1993) Western blotting in the serodiagnosis of Lyme disease. Journal of infectious diseases, 167(2): 392-400
Fingerle, V., Hauser, U., Liegl, G., Petko, B., Preac-Mursic, V., Wilske, B. (1995) Expression of outer surface proteins A and C of Borrelia burgdorferi in Ixodes ricinus. Journal of clinical microbiology, 33(7): 1867-9
Fingerle, V., Laux, H., Munderloh, U.G., Schulte-Spechtel, U., Wilske, B. (2000) Differential expression of outer surface proteins A and C by individual Borrelia burgdorferi in different genospecies. Medical microbiology and immunology, 189(2): 59-66
Fingerle, V., Schulte-Spechtel, U.C., Ruzic-Sabljic, E., Leonhard, S., Hofmann, H., Weber, K., Pfister, K., Strle, F., Wilske, B. (2008) Epidemiological aspects and molecular characterization of Borrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. International Journal of Medical Microbiology, 298(3-4): 279-290
Girschick, H.J., Morbach, H., Tappe, D. (2009) Treatment of Lyme borreliosis. Arthritis research & therapy, 11(6): 258
Gray, J.S., Kahl, O., Lane, R.S., Stanek, G. (2002) Lyme borreliosis: biology, epidemiology and control. New York: CABI Publishing, 368 p
Hubalek, Z. (2009) Epidemiology of lyme borreliosis. Curr Probl Dermatol, 37, str. 31-50
Hunfeld, K.P., Kraiczy, P., Wichelhaus, T.A., Schäfer, V., Brade, V. (2000) Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. International journal of antimicrobial agents, 15(1): 11-7
Hunfeld, K.P., Kraiczy, P., Wichelhaus, T.A., Schäfer, V., Brade, V. (2000) New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. European journal of clinical microbiology & infectious diseases, 19(1): 27-32
Huppertz, H.I., Standeart, S.M., Plotkin, S.A. (1999) Incidence of Lyme borreliosis in the Wurzburg Region of Germany. European Journal of Clinical Microbiology & Infectious Diseases, 18(10): 697-703
Kristoferitsch, W. (1991) Neurological manifestations of Lyme borreliosis: Clinical definition and differential diagnosis. Scand J Infect Dis Suppl, 77: 64-73
Lotric-Furlan, S., Cimperman, J., Maraspin, V., Ruzić-Sabljić, E., Logar, M., Jurca, T., Strle, F. (1999) Lyme borreliosis and peripheral facial palsy. Wiener klinische Wochenschrift, 111(22-23): 970-5
Maraspin, V., Ružić-Sabljić, E., Strle, F., Cimperman, J., Jereb, M., Preac-Mursic, V. (1995) Persistence of Borrelia burgdorferi after treatment with antibiotics. Alpe Adria Microbiol J., 3: 211-216
Maraspin, V., Ruzic-Sabljic, E., Strle, F. (2006) Lyme borreliosis and Borrelia spielmanii. Emerging infectious diseases, 12(7): 1177
Masuzawa, T., Kurita, T., Kawabata, H., Yanagihara, Y. (1994) Relationship between infectivity and OspC expression in Lyme disease Borrelia. FEMS Microbiology Letters, 123(3): 319-324
Menne, B., Ebi, K.L. (2006) Climate change and adaptation strategies for human health. Darmstadt: Steinkopff, 449 p; http://www.batut.org.rs/index.php?content=1168 (15.05.2015)
Morgenstern, K., Baljer, G., Norris, D.E., Kraiczy, P., Hanssen-Hübner, C., Hunfeld, K. (2009) In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease. Antimicrobial agents and chemotherapy, 53(3): 1281-4
Mursic, V.P., Busch, U., Marget, W., Rigler, D.P., Hagl, S. (1996) Kill kinetics ofBorrelia burgdorferi and bacterial findings in relation to the treatment of lyme borreliosis. Infection, 24(1): 9-16
Pal, U., de Silva, A.M., Montgomery, R.R., Fish, D., Anguita, J., Anderson, J.F., Lobet, Y., Fikrig, E. (2000) Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A. Journal of clinical investigation, 106(4): 561-9
Pal, U., Fikrig, E. (2003) Adaptation of Borrelia burgdorferi in the vector and vertebrate host. Microbes and infection, 5(7): 659-66
Rijpkema, S.G.T., Tazelaar, D.J., Molkenboer, M.J.C.H., Noordhoek, G.T., Plantinga, G., Schouls, L.M., Schellekens, J.F.P. (1997) Detection of Borrelia afzelii, Borrelia burgdorferi sensu stricto, Borrelia garinii and group VS116 by PCR in skin biopsies of patients with erythema migrans and acrodermatitis chronica atrophicans. Clinical microbiology and infection, 3(1): 109-116
Robinson, J.M., Pilot-Matias, T.J., Pratt, S.D., Patel, C.B., Bevirt, T.S., Hunt, J.C. (1993) Analysis of the humoral response to the flagellin protein of Borrelia burgdorferi: cloning of regions capable of differentiating Lyme disease from syphilis. Journal of clinical microbiology, 31(3): 629-35
Rudenko, N., Golovchenko, M., Grubhoffer, L., Oliver, J.H. (2011) Updates on Borrelia burgdorferi sensu lato complex with respect to public health. Ticks and tick-borne diseases, 2(3): 123-8
Ruzić-Sabljić, E., Podreka, T., Maraspin, V., Strle, F. (2005) Susceptibility of Borrelia afzelii strains to antimicrobial agents. International journal of antimicrobial agents, 25(6): 474-8
Ružić-Sabljić, E., Maraspin, V., Lotrič-Furlan, S., Jurca, T., Logar, M., Pikelj-Pečnik, A., Strle, F. (2002) Characterization of Borrelia burgdorferi sensu lato strains isolated from human material in Slovenia. Wien Klin Wochenschr, 114: 544-550
Ružić-Sabljić, E., Lotrič-Furlan, S., Maraspin, V., Cimperman, J., Logar, M., Jurca, T., Strle, F. (2006) Comparison of isolation rate of Borrelia burgdorferi sensu lato in MKP and BSK-II medium. International Journal of Medical Microbiology, 296: 267-273
Ryffel, K., Peter, O., Rutti, B., Suard, A., Dayer, E. (1999) Scored antibody reactivity determined by immunoblotting shows an association between clinical manifestations and presence of Borrelia burgdorferi sensu stricto, B. garinii, B. afzelii, and B. Valaisiana in humans. J Clin Microbiol, 37(12): 4086-92
Scheffold, N., Herkommer, B., Kandolf, R., May, A.E. (2015) Lyme carditis-diagnosis, treatment and prognosis. Dtsch Arztebl Int., 112(12); 20220-2028
Sicklinger, M., Wienecke, R., Neubert, U. (2003) In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. Journal of clinical microbiology, 41(4): 1791-3
Sigal, L.H., Zahradnik, J.M., Lavin, P., Patella, S.J., Bryant, G., Haselby, R., Hilton, E., Kunkel, M., Adler-Klein, D., Doherty, T., Evans, J., Molloy, P.J., Seidner, A.L., Sabetta, J.R., Simon, H.J., Klempner, M.S., Mays, J., Marks, D., Malawista, S.E. (1998) A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med., 339: 21-22
Stanek, G., Baradaran-Dilmaghani, R. (1996) In vitro susceptibility of thirtyBorrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection, 24(1): 60-63
Stanek, G., Fingerle, V., Hunfeld, K.-P., Jaulhac, B., Kaiser, R., Krause, A., Kristoferitsch, W., O`Connell, S., Ornstein, K., Strle, F., Gray, J. (2011) Lyme borreliosis: Clinical case definitions for diagnosis and management in Europe. Clinical Microbiology and Infection, 17(1): 69-79
Stanek, G., Strle, F. (2003) Lyme borreliosis. Lancet, 3362, 1639-47
Stanek, G., Wormser, G.P., Gray, J., Strle, F. (2012) Lyme borreliosis. Lancet, 379(9814): 461-473
Steere, A.C. (2001) Lyme disease. N Engl J Med, 345(2): 115-25
Steere, A.C., Sikand, V.K., Meurice, F., Parenti, D.L., Fikrig, E., Schoen, R.T., Nowakowski, J., Schmid, C.H., Laukamp, S., Buscarino, C., Krause, D.S. (1998) Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med, 339(4): 209-15
Steere, A.C., Coburn, J., Glickstein, L. (2004) The emergence of Lyme disease. J Clin Invest, 113(8): 1093-101
Strle, F., Nadelman, R.B., Cimperman, J., Nowakowski, J., Picken, R.N., Schwartz, I., Maraspin, V., Aguero-Rosenfeld, M.E., Varde, S., Lotrič-Furlan, S., Wormser, G.P. (1999) Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med., 130: 32-36
Strle, F. (1999) Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien Klin Wochenschr, 111(22-23): 911-5
Strle, F., Nelson, J.A., Ružić, A., Picken, R.N. (2002) European Lyme borreliosis: 231 culture-confirmed cases involving patient with erythema migrans. Clin Infect Dis, 23, str. 61-5
Strle, F., Ruzić-Sabljić, E., Cimperman, J., Lotric-Furlan, S., Maraspin, V. (2006) Comparison of findings for patients with Borrelia garinii and Borrelia afzelii isolated from cerebrospinal fluid. Clinical infectious diseases, 43(6): 704-10
Strle, F. (1999) Lyme borreliosis in Slovenia. Zentralblatt für Bakteriologie, 289(5-7): 643-652
Strle, F., Stanek, G. (2009) Clinical Manifestations and Diagnosis of Lyme Borreliosis. Current Problems in Dermatology, 37:51-110
Veinović, G., Cerar, T., Strle, F., Lotrič-Furlan, S., Maraspin, V., Cimperman, J., Ružić-Sabljić, E. (2013) In vitro susceptibility of European human Borrelia burgdorferi sensu stricto strains to antimicrobial agents. International journal of antimicrobial agents, 41(3): 288-91
Wang, G., Dam, A.P., Schwartz, I., Dankert, J. (1999) Molecular typing of Borrelia burgdorferi sensu lato: Taxonomic, epidemiological, and clinical implications. Clinical microbiology reviews, 12(4): 633-53
Wilske, B., Busch, U., Fingerle, V., Jauris-Heipke, S., Mursic, V.P., Rössler, D., Will, G. (1996) Immunological and molecular variability of OspA and OspC. implications forBorrelia vaccine development. Infection, 24(2): 208-212
Wormser, G.P., Nadelman, R.B., Dattwyler, R.J., Dennis, D.T., Shapiro, E.D., Steere, A.C., Rush, T.J., Rahn, D.W., Coyle, P.K., Persing, D.H., Fish, D., Luft, B.J. (2000) Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis, 31 Suppl 1: 1-14
 

O članku

jezik rada: srpski
vrsta rada: stručni članak
DOI: 10.5937/arhfarm1502129V
objavljen u SCIndeksu: 11.01.2016.

Povezani članci

Acta veterinaria (2011)
Lajm neuroborelioza
Milovanović Aleksandar, i dr.

Medicinski pregled (2010)
Lajmska bolest - dijagnostičke teškoće u interpretaciji seroloških rezultata
Gajović Olgica, i dr.

Veterinarski glasnik (2013)
Prevalencija antitela klase G na antigene uzročnika lajmske bolesti kod pasa u Vojvodini, Srbija
Potkonjak Aleksandar, i dr.

prikaži sve [22]